Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

Eur J Haematol. 2004 Apr;72(4):302-3. doi: 10.1111/j.1600-0609.2004.00212.x.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asparaginase / administration & dosage
  • Benzamides
  • Doxorubicin / administration & dosage
  • Drug Resistance, Neoplasm*
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Humans
  • Imatinib Mesylate
  • Male
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Recurrence, Local
  • Piperazines / administration & dosage*
  • Piperazines / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Prednisone / administration & dosage
  • Pyrimidines / administration & dosage*
  • Pyrimidines / therapeutic use
  • Remission Induction
  • Stem Cell Transplantation
  • Transplantation, Homologous
  • Vincristine / administration & dosage

Substances

  • Benzamides
  • Neoplasm Proteins
  • Piperazines
  • Pyrimidines
  • Vincristine
  • Doxorubicin
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Asparaginase
  • Prednisone